Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab +/- BMS-986205 and BCG in NMIBC
NCT03519256Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2018
- Primary completion
- Aug 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 2 trial of nivolumab, linrodostat in non-muscle-invasive bladder cancer (NMIBC), sponsored by Bristol Myers Squibb. Started Aug 2018; status: terminated.
02
Drugs
nivolumablinrodostat
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT03519256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03519256.